BofA Downgrades Forest Labs

Analyst David Maris sees risk for the pharmaceutical outfit's upcoming Lexapro trial

Banc of America downgrades generic drug-maker Forest Labs (FRX ) to sell from neutral.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.